Skip to main content


Currently, the cancer microbiome sequencing industry is witnessing an upsurge due to the increasing emphasis on the microbiome’s potential in the field of cancer, global increase in cancer prevalence, and decreasing cost of sequencing. Furthermore, biotechnology companies are focusing on developing cancer microbiome sequencing solutions for applications, including translational research and diagnostics, further supporting researchers and clinicians to unravel insights pertaining to microbiome's influence on cancer manifestation and progression. The development of cancer microbiome sequencing products and services enabled the research community to establish effective strategies for discovering novel cancer biomarkers associated with the microbiome, which could be harnessed for the development of cancer microbiome sequencing products for clinical use. Cancer microbiome sequencing is predicted to grow at a CAGR of 20.01% over the forecast period of 2021-2031.


Comments